A comprehensive analysis of the prognostic value, expression characteristics and immune correlation of MKI67 in cancers
Backgroundnuclear-associated antigen Ki67 (Ki67) emerges as a clinically practical biomarker for proliferation assessment among many cancer types. However, the definite prognostic value of Ki67 against a specific cancer type has remained vague. This study aims to perform a comprehensive pan-cancer a...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1531708/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850080911041757184 |
|---|---|
| author | Xiaolan Pan Caibiao Wei Jingyu Su Min Fang Qiumei Lin Yuling Qin Jie Gao Jie Zhao Huiliu Zhao Fengfei Liu |
| author_facet | Xiaolan Pan Caibiao Wei Jingyu Su Min Fang Qiumei Lin Yuling Qin Jie Gao Jie Zhao Huiliu Zhao Fengfei Liu |
| author_sort | Xiaolan Pan |
| collection | DOAJ |
| description | Backgroundnuclear-associated antigen Ki67 (Ki67) emerges as a clinically practical biomarker for proliferation assessment among many cancer types. However, the definite prognostic value of Ki67 against a specific cancer type has remained vague. This study aims to perform a comprehensive pan-cancer analysis of the prognosis value of Ki67 across various cancer types.MethodsThis study explored the expression, prognostic value, and tumor-infiltrating immune of MKI67 in the TCGA database by pan-cancer, and then performed immunohistochemical, correlation analysis and prognostic analysis using 10028 patients of the top 10 cancer patients in China we collected. The correlation between MKI67 expression and survival outcome, clinical features, MSI, TMB, and tumor-infiltrating immune cells by TCGA database, xCell, and TIMER algorithms.ResultsMKI67 expression was significantly upregulated across varied cancer types verified by datasets. We found MKI67 expression was significantly associated with poor prognosis in LUADLUSC, LIHC, and BRCA patients, but good prognosis in COADREAD and READ patients via Kaplan-Meier survival analysis using 10028 patients collected. These results of our validation were generally consistent with TCGA database except BRCA, COADREAD and READ. Meanwhile, upregulation of MKI67 elevates the degree of immune infiltration of several immune cell subtypes, such as functional T cells, CD4+ T cells, and CD8+ T cells, as well as, MKI67 was related to Cell cycle, Oocyte meiosis, p53 and other pathways.ConclusionOur comprehensive analysis may supply useful guidance on MKI67 applicability across various cancer types. These observed results contribute to the promise of MKI67 in a realistic clinical setting and improve the outcomes of cancer patients. |
| format | Article |
| id | doaj-art-dee268ead52b4b19b7d8a88dca844b42 |
| institution | DOAJ |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-dee268ead52b4b19b7d8a88dca844b422025-08-20T02:44:50ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-02-011610.3389/fimmu.2025.15317081531708A comprehensive analysis of the prognostic value, expression characteristics and immune correlation of MKI67 in cancersXiaolan Pan0Caibiao Wei1Jingyu Su2Min Fang3Qiumei Lin4Yuling Qin5Jie Gao6Jie Zhao7Huiliu Zhao8Fengfei Liu9Department of Clinical Laboratory, Guangxi Medical University Cancer Hospital, Nanning, ChinaDepartment of Clinical Laboratory, Guangxi Medical University Cancer Hospital, Nanning, ChinaGenetic Metabolism Center laboratory, Guangxi Zhuang Autonomous Region Maternal and Child Health Care Hospital, Nanning, ChinaDepartment of Clinical Laboratory, Guangxi Medical University Cancer Hospital, Nanning, ChinaDepartment of Clinical Laboratory, Guangxi Medical University Cancer Hospital, Nanning, ChinaDepartment of Clinical Laboratory, Guangxi Medical University Cancer Hospital, Nanning, ChinaDepartment of Clinical Laboratory, Guangxi Medical University Cancer Hospital, Nanning, ChinaDepartment of Medical Records, Guangxi Medical University Cancer Hospital, Nanning, ChinaDepartment of Clinical Laboratory, Guangxi Medical University Cancer Hospital, Nanning, ChinaDepartment of Clinical Laboratory, Guangxi Medical University Cancer Hospital, Nanning, ChinaBackgroundnuclear-associated antigen Ki67 (Ki67) emerges as a clinically practical biomarker for proliferation assessment among many cancer types. However, the definite prognostic value of Ki67 against a specific cancer type has remained vague. This study aims to perform a comprehensive pan-cancer analysis of the prognosis value of Ki67 across various cancer types.MethodsThis study explored the expression, prognostic value, and tumor-infiltrating immune of MKI67 in the TCGA database by pan-cancer, and then performed immunohistochemical, correlation analysis and prognostic analysis using 10028 patients of the top 10 cancer patients in China we collected. The correlation between MKI67 expression and survival outcome, clinical features, MSI, TMB, and tumor-infiltrating immune cells by TCGA database, xCell, and TIMER algorithms.ResultsMKI67 expression was significantly upregulated across varied cancer types verified by datasets. We found MKI67 expression was significantly associated with poor prognosis in LUADLUSC, LIHC, and BRCA patients, but good prognosis in COADREAD and READ patients via Kaplan-Meier survival analysis using 10028 patients collected. These results of our validation were generally consistent with TCGA database except BRCA, COADREAD and READ. Meanwhile, upregulation of MKI67 elevates the degree of immune infiltration of several immune cell subtypes, such as functional T cells, CD4+ T cells, and CD8+ T cells, as well as, MKI67 was related to Cell cycle, Oocyte meiosis, p53 and other pathways.ConclusionOur comprehensive analysis may supply useful guidance on MKI67 applicability across various cancer types. These observed results contribute to the promise of MKI67 in a realistic clinical setting and improve the outcomes of cancer patients.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1531708/fullMKI67prognosiscancer immunitypathwaymulti-omics bioinformatics |
| spellingShingle | Xiaolan Pan Caibiao Wei Jingyu Su Min Fang Qiumei Lin Yuling Qin Jie Gao Jie Zhao Huiliu Zhao Fengfei Liu A comprehensive analysis of the prognostic value, expression characteristics and immune correlation of MKI67 in cancers Frontiers in Immunology MKI67 prognosis cancer immunity pathway multi-omics bioinformatics |
| title | A comprehensive analysis of the prognostic value, expression characteristics and immune correlation of MKI67 in cancers |
| title_full | A comprehensive analysis of the prognostic value, expression characteristics and immune correlation of MKI67 in cancers |
| title_fullStr | A comprehensive analysis of the prognostic value, expression characteristics and immune correlation of MKI67 in cancers |
| title_full_unstemmed | A comprehensive analysis of the prognostic value, expression characteristics and immune correlation of MKI67 in cancers |
| title_short | A comprehensive analysis of the prognostic value, expression characteristics and immune correlation of MKI67 in cancers |
| title_sort | comprehensive analysis of the prognostic value expression characteristics and immune correlation of mki67 in cancers |
| topic | MKI67 prognosis cancer immunity pathway multi-omics bioinformatics |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1531708/full |
| work_keys_str_mv | AT xiaolanpan acomprehensiveanalysisoftheprognosticvalueexpressioncharacteristicsandimmunecorrelationofmki67incancers AT caibiaowei acomprehensiveanalysisoftheprognosticvalueexpressioncharacteristicsandimmunecorrelationofmki67incancers AT jingyusu acomprehensiveanalysisoftheprognosticvalueexpressioncharacteristicsandimmunecorrelationofmki67incancers AT minfang acomprehensiveanalysisoftheprognosticvalueexpressioncharacteristicsandimmunecorrelationofmki67incancers AT qiumeilin acomprehensiveanalysisoftheprognosticvalueexpressioncharacteristicsandimmunecorrelationofmki67incancers AT yulingqin acomprehensiveanalysisoftheprognosticvalueexpressioncharacteristicsandimmunecorrelationofmki67incancers AT jiegao acomprehensiveanalysisoftheprognosticvalueexpressioncharacteristicsandimmunecorrelationofmki67incancers AT jiezhao acomprehensiveanalysisoftheprognosticvalueexpressioncharacteristicsandimmunecorrelationofmki67incancers AT huiliuzhao acomprehensiveanalysisoftheprognosticvalueexpressioncharacteristicsandimmunecorrelationofmki67incancers AT fengfeiliu acomprehensiveanalysisoftheprognosticvalueexpressioncharacteristicsandimmunecorrelationofmki67incancers AT xiaolanpan comprehensiveanalysisoftheprognosticvalueexpressioncharacteristicsandimmunecorrelationofmki67incancers AT caibiaowei comprehensiveanalysisoftheprognosticvalueexpressioncharacteristicsandimmunecorrelationofmki67incancers AT jingyusu comprehensiveanalysisoftheprognosticvalueexpressioncharacteristicsandimmunecorrelationofmki67incancers AT minfang comprehensiveanalysisoftheprognosticvalueexpressioncharacteristicsandimmunecorrelationofmki67incancers AT qiumeilin comprehensiveanalysisoftheprognosticvalueexpressioncharacteristicsandimmunecorrelationofmki67incancers AT yulingqin comprehensiveanalysisoftheprognosticvalueexpressioncharacteristicsandimmunecorrelationofmki67incancers AT jiegao comprehensiveanalysisoftheprognosticvalueexpressioncharacteristicsandimmunecorrelationofmki67incancers AT jiezhao comprehensiveanalysisoftheprognosticvalueexpressioncharacteristicsandimmunecorrelationofmki67incancers AT huiliuzhao comprehensiveanalysisoftheprognosticvalueexpressioncharacteristicsandimmunecorrelationofmki67incancers AT fengfeiliu comprehensiveanalysisoftheprognosticvalueexpressioncharacteristicsandimmunecorrelationofmki67incancers |